New drug cocktail shows promise in slowing rare sarcoma
NCT ID NCT04028063
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two immunotherapy drugs (zalifrelimab and balstilimab) to standard chemotherapy (doxorubicin) can help control advanced or metastatic soft tissue sarcoma for longer. About 65 adults with sarcoma that cannot be removed by surgery will receive the combination. The main goal is to see if the cancer stays stable for at least 6 months, compared to historical results with chemotherapy alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own immune cells fight advanced sarcoma?
- Can an immune-boosting drug make chemotherapy more effective against sarcoma?
- Immunotherapy boosts chemo against rare sarcomas?
- New mRNA shot targets Hard-to-Treat cancers in early human test
- New hope for sarcoma patients: drug slows tumor growth in late-stage trial
- Cancer drug shows promise in keeping sarcoma in check